利妥昔单抗联合GDP方案在复发难治性非霍奇金淋巴瘤患者中的应用  

Application of Rituximab Combined with GDP Regimen in Patients with Recurrent Refractory Non-Hodgkin's Lymphoma

作　　者：索萌萌 王艳美 闫明明 SUO Mengmeng;WANG Yanmei;YAN Mingming(2^(nd) Ward of Department of Oncology,the First Affiliated Hospital of He'nan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学第一附属医院肿内二病区,河南洛阳471003

出　　处：《临床医学工程》2021年第10期1375-1376,共2页Clinical Medicine & Engineering

摘　　要：目的探讨利妥昔单抗联合GDP方案在复发难治性非霍奇金淋巴瘤(NHL)患者中的应用效果。方法65例复发难治性NHL患者根据治疗方法的不同分为观察组(n=32)和对照组(n=33)。对照组采用GDP方案化疗,观察组在对照组基础上给予利妥昔单抗。比较两组治疗前后的VEGF、TK-1水平以及不良反应。结果治疗2个周期后,两组的VEGF、TK-1水平均显著低于治疗前,且观察组的VEGF、TK-1水平均显著低于对照组(P<0.05)。治疗期间,两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论利妥昔单抗联合GDP方案治疗复发难治性NHL效果显著,可有效抑制患者肿瘤细胞增殖,且不会明显增加不良反应。Objective To explore the application effect of rituximab combined with GDP regimen in patients with recurrent refractory non-Hodgkin's lymphoma(NHL).Methods 65 patients with recurrent refractory NHL were divided into the observation group(n=32)and the control group(n=33)according to different treatment methods.The control group was given GDP chemotherapy,and the observation group was given rituximab on the basis of the control group.The levels of VEGF and TK-1 before and after treatment,and the adverse reactions were compared between the two groups.Results After two cycles of treatment,the levels of VEGF and TK-1 of the two groups were significantly lower than those before treatment,and the levels of VEGF and TK-1 in the observation group were significantly lower than those in the control group(P<0.05).During the treatment,no significant difference was found in the incidences of adverse reactions between the two groups(P>0.05).Conclusions Rituximab combined with GDP regimen in the treatment of recurrent refractory NHL has significant effect,and can effectively inhibit the proliferation of tumor cells of patients without significantly increasing adverse reactions.

关 键 词：复发难治性非霍奇金淋巴瘤 利妥昔单抗 GDP方案 

分 类 号：R733.4[医药卫生—肿瘤]